Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Balazs Halmos

Showing results (141-150 of 221) with videos related to

Pageof 23
Sort By:
Nature Cancer|October 18, 2021
Patterns of seroconversion for SARS-CoV2-IgG in patients with malignant disease and association with anticancer therapyAstha Thakkar, Kith Pradhan, Shawn Jindal, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 14, 2014
A randomized, phase 2 trial of Docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic non-small-cell lung cancerBenjamin Levy, Alexander Spira, Daniel Becker, et al.
Lung Cancer (Amsterdam, Netherlands)|January 14, 2026
SEZ6 expression and lineage plasticity in small cell lung cancer and transformed non-small cell lung cancerJennifer A Marks, Kieran Sweeney, Andrew Elliott, et al.
Cancer Research|April 8, 2025
SCD1 Inhibition Blocks the AKT-NRF2-SLC7A11 Pathway to Induce Lipid Metabolism Remodeling and Ferroptosis Priming in Lung AdenocarcinomaUtsav Sen, Charles Coleman, Nishant Gandhi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2009
Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancerRom S Leidner, Pingfu Fu, Bradley Clifford, et al.
Lung Cancer (Amsterdam, Netherlands)|September 6, 2024
Molecular profiling METex14+ non-small cell lung cancer (NSCLC): Impact of histologyJennifer A Marks, Nishant Gandhi, Balazs Halmos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2017
MET-GRB2 Signaling-Associated Complexes Correlate with Oncogenic MET Signaling and Sensitivity to MET Kinase InhibitorsMatthew A Smith, Thomas Licata, Aliya Lakhani, et al.
Translational Lung Cancer Research|June 24, 2021
Impact of chronic obstructive pulmonary disease on immune checkpoint inhibitor efficacy in advanced lung cancer and the potential prognostic factorsJiebai Zhou, Yencheng Chao, Danwei Yao, et al.
Lung Cancer (Amsterdam, Netherlands)|January 16, 2019
Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: Results from a global real-world study (RealGiDo)Balazs Halmos, Eng-Huat Tan, Ross A Soo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 19, 2018
Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC)Shirish M Gadgeel, Nathan A Pennell, Mary Jo Fidler, et al.
Pageof 23

Showing results (141-150 of 221) with videos related to

Sort By:
Pageof 23
Nature Cancer|October 18, 2021
Patterns of seroconversion for SARS-CoV2-IgG in patients with malignant disease and association with anticancer therapyAstha Thakkar, Kith Pradhan, Shawn Jindal, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 14, 2014
A randomized, phase 2 trial of Docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic non-small-cell lung cancerBenjamin Levy, Alexander Spira, Daniel Becker, et al.
Lung Cancer (Amsterdam, Netherlands)|January 14, 2026
SEZ6 expression and lineage plasticity in small cell lung cancer and transformed non-small cell lung cancerJennifer A Marks, Kieran Sweeney, Andrew Elliott, et al.
Cancer Research|April 8, 2025
SCD1 Inhibition Blocks the AKT-NRF2-SLC7A11 Pathway to Induce Lipid Metabolism Remodeling and Ferroptosis Priming in Lung AdenocarcinomaUtsav Sen, Charles Coleman, Nishant Gandhi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2009
Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancerRom S Leidner, Pingfu Fu, Bradley Clifford, et al.
Lung Cancer (Amsterdam, Netherlands)|September 6, 2024
Molecular profiling METex14+ non-small cell lung cancer (NSCLC): Impact of histologyJennifer A Marks, Nishant Gandhi, Balazs Halmos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2017
MET-GRB2 Signaling-Associated Complexes Correlate with Oncogenic MET Signaling and Sensitivity to MET Kinase InhibitorsMatthew A Smith, Thomas Licata, Aliya Lakhani, et al.
Translational Lung Cancer Research|June 24, 2021
Impact of chronic obstructive pulmonary disease on immune checkpoint inhibitor efficacy in advanced lung cancer and the potential prognostic factorsJiebai Zhou, Yencheng Chao, Danwei Yao, et al.
Lung Cancer (Amsterdam, Netherlands)|January 16, 2019
Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: Results from a global real-world study (RealGiDo)Balazs Halmos, Eng-Huat Tan, Ross A Soo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 19, 2018
Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC)Shirish M Gadgeel, Nathan A Pennell, Mary Jo Fidler, et al.
Pageof 23